Short answer
CVS Health (CVS) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Larry M. Robbins resigned from CVS Health’s Board effective August 13, 2026.
CVS Health 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Larry M. Robbins resigned from CVS Health’s Board effective August 13, 2026
- Resignation unrelated to disagreements over company operations, policies, or practices
- Teresa Heitsenrether joins the Board effective November 18, 2026
- Heitsenrether brings JPMorgan Chase data, analytics, securities services, and financing experience
- Board classified Heitsenrether as independent under NYSE and CVS governance standards
Item 7.01 · Regulation FD Disclosure
- No substantive Item 7.01 disclosure provided
- Filing contains only execution by CVS Health’s authorized officer dated August 17, 2026
Item EX-99.1 · Exhibit EX-99.1
- Teresa Heitsenrether joins CVS’s Board effective November 18, 2026, adding data, analytics, AI and technology-transformation expertise
- Heitsenrether’s JPMorgan operating background supports CVS’s stated strategy to become a consumer-focused health technology company
- Larry Robbins departed the Board effective August 13, 2026, after serving since 2024
- Robbins’s exit removes a financial and healthcare-industry perspective from the Audit and Public Policy and External Affairs Committees
- Board transition follows CVS’s governance refresh and focus on operating performance, financial discipline and technology investment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CVS Health 8-K filings
Get the next CVS 8-K as it lands
Follow CVS for push alerts, or ask the research agent what this filing means.